|
 |
European Pharmaceutical Contractor
|
Industry Overview
Over the last few years, the European pharmaceutical and biotechnology industries have been assailed by a series of events that have led to stagnation, re-organisation and increased merger and acquisition activity. The landscape of the pharmaceutical and biotechnology industries has changed forever.
The genomics revolution, the proteomics revolution, combinatorial chemistry and dozens of other 'new' technologies promised a golden age where new biotechnology businesses could shortcut the time taken to produce new drugs, where medicines could have efficacy and safety designed-in from day one and where all sorts of diseases would be 'cured' in no time at all. People were anxious to be a part of the inevitable rush to profits and queued up to invest.
The promise has failed to materialise, however, and investors in biotechnology have slowly become aware that creating new drugs is a long-term, high risk, high investment game. At the same time, pharmaceutical companies have come to understand that their biotechnology partners are often no better placed than they are to produce step changes in productivity (indeed, many of the 'new' technologies are now mundane) and so have withdrawn or limited their investment. So, no new money has meant a tightening of belts and a rash of mergers and acquisitions in the biotechnology sector - insecurity equals fear and frightened people do not move jobs unless they really have to.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Robert Bates, Managing Director of RSA GmbH and Nick Stephens, Managing Director at RSA Consulting Ltd
Robert Bates is Managing Director of RSA GmbH. Robert joined RSA to open the Frankfurt office in April 2004. Prior to that he had gained seven years of life sciences recruitment experience based in Brussels and Frankfurt. Robert brings more than 25 years' industry knowledge in medical devices, biologics and parenteral product experiences in positions ranging from R&D through to Regional General Manager, with strong staff management and strategic business development responsibilities. A graduate of the University of Iowa in Medical Technology and Biology, he has worked for multinational companies like Baxter and Fresenius Medical Care.
Nick Stephens has been a Director of RSA Consulting Ltd since 1986, having joined as a full-time consultant in 1995. In January 2000, he was appointed Managing Director of RSA Consulting Ltd - the RSA 'group' company. He also heads the medical practice within RSA Search & Selection and helps clients to find and place the best senior executives in a range of disciplines from general management to clinical research. Nick has broad experience in pharmaceutical recruitment, information systems, logistics and distribution, marketing, media relations, sales and strategic planning and an understanding of the mindsets and needs of owners, managers and staff at various levels.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
“PACK DIFFERENT” with EMBALLAGE 2008
“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >> |
|
 |
